Aug 1, 2011
By:
William Looney
What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders
|
|
Aug 1, 2011
By:
William Looney
A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation.
|
Jul 1, 2011
By:
William Looney
More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them
|
Jul 1, 2011
By:
William Looney
Pfizer's crizotinib development program combined organization, art, and science—and a large dose of unforeseen risk
|
|
Call it spit and risk—hitting it
Jun 1, 2011
By:
William Looney
With Yankee stadium as the backdrop, Pharm Exec convened its annual panel of eight business development experts to crack the bat on best practice in licensing and M&A for the year ahead.
|
|
Jun 1, 2011
By:
William Looney
Now that government payers are turning to pharma to bridge budgetary shortfalls it's best to think long-term
|
|
May 1, 2011
By:
William Looney
What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
|
Apr 1, 2011
By:
William Looney
Dutch-based DSM N.V. is seeking innovatinve ways to partner through bolstering manufacturing
|
Apr 1, 2011
By:
William Looney
A true performance culture has to focus on the mundane as much as the sublime
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
